Search Results

Prime Therapeutics LLC/Magellan Rx Management, LLC (Prime), a leading pharmacy solutions organization, and Capital Rx, Inc. (Capital Rx), a renowned health care technology solutions provider, are announcing a strategic alliance.

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to support it. Meanwhile, the makers of these drugs have been reporting double-digit sales growth for many of these products.

Prime Therapeutics, LLC/Magellan Rx Management announces the appointment of health care leader Mike Edwards as president, markets.

Prime Medicine, Inc. today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer will present at two upcoming investor conferences.

In an effort to expand its cash runway beyond 12 months, Prime Medicine has signed a deal with Bristol Myers Squibb worth a potential $3.5 billion, while also streamlining its pipeline to trim costs.

Lykos Therapeutics is currently working out ways to fund an additional Phase III study for its MDMA-assisted PTSD therapy following an FDA setback last year.

Prime Medicine, Inc. today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at the 3rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024); the American Society of Cell & Gene Therapy 27th Annual Meeting.